SCHEMBL20128569

SCHEMBL20128569

Cn1c2ccncc2c2cc(F)c(-c3ccc(O)nc3)cc21

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 7/20 0.36
TOP2A P11388 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34
RPS6KA2 Q15349 1/20 0.34
RPS6KA1 Q15418 1/20 0.34
CYP3A4 P08684 3/20 0.34
CYP1A2 P05177 2/20 0.34
TGFBR1 P36897 2/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
ROCK2 O75116 1/20 0.32
GRIN1 Q05586 2/20 0.32
GRIN2B Q13224 1/20 0.32
ABCC1 P33527 1/20 0.32
ACHE P22303 1/20 0.32
GRIN2A Q12879 1/20 0.32
MAPT P10636 1/20 0.32
MAPK10 P53779 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20128575 0.89 MAPT (0.41) RPS6KA3TOP2ACYP3A4MAOAMAOB
SCHEMBL20128573 0.84 ADORA3 (0.41) RPS6KA3TOP2AADORA3ADORA2ARPS6KA2
SCHEMBL20128567 0.84 TDO2 (0.45) TOP2ACYP3A4MAOAMAPT
SCHEMBL20128566 0.82 NPC1 (0.43) TOP2AADORA3ADORA2AMAOAMAOB
SCHEMBL20128571 0.80 TOP2A (0.38) RPS6KA3TOP2AADORA3ADORA2ARPS6KA2
SCHEMBL20128578 0.73 MAPT (0.43) TOP2AADORA3ADORA2ACYP3A4ROCK2
SCHEMBL29547590 0.73 MAPT (0.48) TOP2AROCK2GRIN1GRIN2BMAPT
SCHEMBL14134198 0.73 MAPT (0.48) TOP2AROCK2GRIN1GRIN2BMAPT
SCHEMBL20129111 0.72 GRIN1 (0.43) ROCK2GRIN1GRIN2BMAPT
SCHEMBL27097193 0.72 GRIN2B (0.42) TOP2AGRIN1GRIN2BMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2023-06-15 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2020-05-21 US disclosed
US-20200155689-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2020-05-21 US disclosed
WO-2019199816-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. (US) 2019-10-17 WO disclosed
WO-2018144649-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME Arvinas, Inc. (US) 2018-08-09 WO disclosed
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME ARVINAS OPERATIONS, INC. 2018-08-02 US disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183209-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 RPS6KA3 2052/4885TOP2A 2786/4885ADORA3 4166/4885
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN RPS6KA3 1841/4885TOP2A 2219/4885ADORA3 4249/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 RPS6KA3 2140/4885TOP2A 2681/4885ADORA3 4137/4885
US-20200155690-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 RPS6KA3 2052/4885TOP2A 2786/4885ADORA3 4166/4885
US-20200155689-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 RPS6KA3 2052/4885TOP2A 2786/4885ADORA3 4166/4885
US-20180215731-A1 CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME CRBN, CBL, MDM2 RPS6KA3 2052/4885TOP2A 2786/4885ADORA3 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.